Connect with us

Hi, what are you looking for?

Chronic Obstructive Pulmonary Disease Drugs Market To Rising in the 7MM By 2030, Analysis by DelveInsight

Chronic Obstructive Pulmonary Disease Drugs Market To Rising in the 7MM By 2030, Analysis by DelveInsight

“Chronic Obstructive Pulmonary Disease Market”

(Albany, US) DelveInsight’s Chronic Obstructive Pulmonary Disease (COPD) Market report” puts forward a detailed perspective on epidemiology, current treatment practices, emerging drugs, COPD market share of the individual therapies, current and forecasted Chronic Obstructive Pulmonary Disease market size for the study period 2019 to 2032 spanning across 7MM (the USA, EU5 (the UK, Italy, Spain, France, and Germany), and Japan).


Chronic Obstructive Pulmonary Disease: An Overview

Chronic Obstructive Pulmonary Disease is a major health problem characterized by progressive airflow limitation and tissue destruction. It is majorly of two types: Chronic Bronchitis and Emphysema. Chronic bronchitis results in inflammation and irritation of the airways making the lining of the airways thick, whereas Emphysema damages the walls of the alveolar sacs reducing the amount of gas exchange in the lungs. With the advances in every field such as medical technology and awareness of the disease, huge strides of improvements have been taken in properly mapping the COPD epidemiology, clinical features and presentation, associated comorbidities, and treatment.


Download Free Sample Report Now @


Some of the key highlights of the Chronic Obstructive Pulmonary Disease Market Report

  • The diagnosed prevalent cases of COPD in the 7MM were 34,640,030 in 2020. These cases are expected to increase throughout the forecast period, i.e., 2021–2032.
  • The estimates suggest a higher diagnosed prevalence of COPD in the United States with 17,455,605 diagnosed cases in 2020 which is expected to increase during the forecast period (2021–2032).
  • In 2020, a lower number of males were affected by this disease contributing 6,588,516 total diagnosed prevalent population of COPD in the United States. In comparison, there were 10,867,088 females affected by COPD in 2020, in the US
  • In the epidemiology model of COPD, there are multiple age groups referred to ranging from 18–44 years, 45–54 years, 55–64 years, 64–74 years, and 75+ years, for COPD. In the US, the highest number of cases were reported in the age group of 55–64 years i.e. 4,601,558, in 2020.
  • The majority of cases of COPD are female in the US. But in EU-5 and Japan, the diagnosed cases of COPD in males represent the majority of the cases. Overall, in the 7MM, females are predominantly high in number.
  • In 2020, the US had 2,967,453, 8,727,802, 4,538,457 and 1,221,892 cases of GOLD 1, GOLD 2, GOLD 3, and GOLD 4 criteria, respectively based on severity of airflow limitation.
  • Among the total diagnosed prevalent cases of COPD in the US, 53% were acquired by GOLD A based on symptoms and exacerbation history. The rest of the cases were occupied by other types 27% by GOLD B, 8% by GOLD C, and 12% by GOLD D.
  • Among the five major European countries, Germany has the highest diagnosed prevalent population followed by Italy and France. On the other hand, Spain had the lowest diagnosed prevalent population.


Chronic Obstructive Pulmonary Disease Epidemiology 

Chronic Obstructive Pulmonary Disease is currently the third most common cause of global morbidity and mortality. As per COPD epidemiological analysis, COPD is primarily present in smokers, especially in the age group >40 years. The COPD prevalence increases with the age, however, the prevalence is most likely underestimated owing to the underdiagnosis of COPD. Chronic Obstructive Pulmonary Disease Market Insights Report offers historical as well as forecasted epidemiological analysis during the study period 2018-30 in the 7MM segmented into:

  • Total Chronic Obstructive Pulmonary Disease prevalent cases
  • Total age-specific diagnosed COPD prevalent cases
  • Total gender-specific diagnosed COPD prevalent cases
  • Total subtype-specific diagnosed COPD prevalent cases
  • Total COPD treatable and diagnosed cases
  • Total severity-specific diagnosed COPD prevalent cases


Visit for deep insights into the COPD patient pool @


Chronic Obstructive Pulmonary Disease Market

The primary goal of COPD treatment remains to alleviate symptoms and address exacerbations, reduce mortality rate, and alter the underlying nature of the disease (otherwise known as ‘disease modification’). Currently, there are 9 approved drug categories for COPD maintenance medication. However, the majority of these available treatment options are largely iterations of bronchodilators, which open airways and but no pharmacological treatment has the potential to prevent the progression of lung destruction. The only way to stop the disease from getting worse is to stop smoking.


Chronic Obstructive Pulmonary Disease Treatment Market

Many people with COPD have mild forms of the disease for which little therapy is needed other than smoking cessation. Even for more advanced stages of the disease, effective therapy is available that can control symptoms, slow progression, reduce the risk of complications and exacerbations, and improve the ability to lead an active life. The goal in treating COPD is to help the person breathe easier and get back to regular activities; many treatments and lifestyle approaches can help. The patient may also try some natural and alternative treatment options. COPD treatment focuses on relieving symptoms, such as coughing, breathing problems, and avoiding respiratory infections. The treatments are often based on the stages of COPD.

Pharmacotherapy for COPD consisted of maintenance and reliever medications. Maintenance medications included inhaled corticosteroid (ICS), long-acting beta-agonist (LABA), fixed-dose combination ICS + LABA, tiotropium (TIO), and inhaled ipratropium or fixed-dose combination ipratropium + albuterol (collectively referred to as ipratropium [IPR]). Reliever medications included short-acting beta-agonist (SABA), oral corticosteroid (OCS), nebulized ipratropium or combination ipratropium–albuterol (collectively referred to as nebulized ipratropium [nebIPR]), and antibiotics.


Chronic Obstructive Pulmonary Disease Marketed Drugs

Duaklir Pressair/Duaklir Genuair (Aclidinium Bromide and Formoterol Fumarate): AstraZeneca/Circassia Pharmaceuticals Inc.

Duaklir (aclidinium bromide/formoterol fumarate 400 µg/12 µg twice-daily) is an approved fixed-dose LAMA/LABA combination of two long-acting bronchodilators – aclidinium bromide is a long-acting muscarinic antagonist (LAMA), and formoterol fumarate is a long-acting beta-agonist (LABA). The fixed-dose combination was approved by the European Medicines Agency (EMA) in November 2014 as a maintenance bronchodilator treatment to relieve symptoms in adult patients with COPD. The pressair is an easy-to-use, multi-dose, breath-activated inhaler with a unique patient feedback mechanism approved in the US for delivering Tudorza (aclidinium bromide). The Pressair inhaler is being used for the development of Duaklir in the US. Outside of the US, the Pressair inhaler is marketed as Genuair.


Advair Diskus/Adoair Diskus/Seretide Diskus (Fluticasone Propionate and Salmeterol Xinafoate): GlaxoSmithKline

Advair Diskus is a combination product of fluticasone propionate + salmeterol xinafoate, which is marketed by GlaxoSmithKline. It is available in three different strengths. One active component of Advair Diskus is fluticasone propionate, which acts as a glucocorticoid receptor agonist (ICS). The other active component of Advair Diskus is salmeterol xinafoate, which acts as a beta 2-adrenoceptor agonist (LABA). The generics versions are available in the US and European markets.


Symbicort (Budesonide and Formoterol Fumarate Dihydrate): AstraZeneca

Symbicort (budesonide + formoterol) combines an inhaled corticosteroid and a fast onset, long-acting beta2-agonist for the maintenance of asthma and COPD, including chronic bronchitis and emphysema, which is marketed by AstraZeneca plc. For patients with COPD, the approved dosage of Symbicort is 160/4.5 mcg, two inhalations twice daily. It combines an inhaled corticosteroid and a fast-onset LABA for the maintenance of asthma and COPD either as Symbicort Turbuhaler or Symbicort pMDI (pressurized metered-dose inhaler).


Chronic Obstructive Pulmonary Disease Emerging Drugs 

Itepekimab (SAR440340/REGN3500/Anti-IL-33 mAb): Sanofi/Regeneron Pharmaceuticals

REGN3500 is a fully human monoclonal antibody that inhibits interleukin-33 (IL-33), a protein that is believed to play a key role in type 1 and type 2 inflammation. The drug is administered subcutaneously. Preclinical research showed REGN3500 blocked several markers of both types of inflammation. Regeneron and Sanofi are currently studying REGN3500 in respiratory and dermatological diseases where inflammation plays an underlying role. REGN3500 is being studied in Phase III trial for chronic obstructive pulmonary disease (COPD), data of which is expected in 2024. 


Dupixent (Dupilumab): Regeneron Pharmaceuticals/Sanofi

Dupixent (dupilumab) is a monoclonal antibody targeting α chain of the interleukin (IL)-4 receptor. It inhibits the biological effects of the cytokines IL-4 and IL-13, which are key drivers in the TH2 response. Dupilumab is approved in the US to treat patients aged ≥12 with moderate-to-severe atopic dermatitis (AD) that is not well controlled with prescription therapies used on the skin (topical), or who cannot use topical therapies. In addition, it is approved for use with other asthma medicines for the maintenance treatment of moderate-to-severe eosinophilic or oral steroid-dependent asthma in patients aged ≥12 whose asthma is not controlled with their current asthma medicines; and for use with other medicines for the maintenance treatment of chronic rhinosinusitis with nasal polyposis (CRSwNP) in adults whose disease is not controlled.


Tyvaso (Inhaled treprostinil solution): United Therapeutics

Treprostinil’s mechanism of action suggests that treprostinil may effectively treat pulmonary hypertension associated with lung disease, including pulmonary hypertension associated with COPD (WHO Group 3 Pulmonary Hypertension). The use of inhaled treprostinil may be the preferred route of administration for treating pulmonary hypertension (PH) in COPD patients as it provides a high dose of treprostinil to the damaged lungs. The company is currently conducting two Phase III clinical trials of inhaled treprostinil to treat PH hypertension associated with COPD (WHO Group 3 Pulmonary Hypertension).


Chronic Obstructive Pulmonary Disease Market Companies

  • Afimmune
  • Allakos
  • Amgen/AstraZeneca
  • Arrowhead Pharmaceuticals
  • Astellas Pharma
  • AstraZeneca
  • Boehringer-Ingelheim
  • Brickell Biotech
  • Chiesi Farmaceutici S.p.A.
  • CHIESI USA, Inc.
  • Dimerix
  • EpiEndo Pharmaceuticals
  • Genentech
  • GlaxoSmithKline
  • GSNOR Therapeutics
  • InMed Pharmaceuticals
  • Ionis Pharmaceuticals
  • KeyMed Biosciences
  • Laboratoires SMB
  • Mereo BioPharma
  • Meridigen Biotech
  • Nephron Pharmaceuticals
  • Novartis
  • Pulmatrix Inc.
  • Pulmotect
  • Quercegen Pharmaceuticals
  • Regend Therapeutics
  • Regeneron Pharmaceuticals/Sanofi
  • Sulfateq BV
  • Synairgen
  • Tetherex Pharmaceuticals
  • Verona Pharma
  • Vertex Pharmaceuticals
  • Yungjin Pharm. Co., Ltd., and Several Others


Chronic Obstructive Pulmonary Disease Market Drivers and Barriers

All of the available drugs and therapies in the COPD therapy market are symptomatic in nature. In the last decade, only one drug has entered the COPD market. However, a better understanding of the disease and its pathophysiology has surged the development of therapies in the COPD market. Besides, a growing prevalence and an aging population are also pushing the market growth.

Novel investigational products in development targeting immune mediators are expected to show promising results on this front. The updated diagnosis paradigm, validation, and approval of patient-reported outcome questionnaires for clinical trials, and drug development tools, such as a prognostic biomarker for patient selection have further helped in stepping up the therapeutic approaches that are efficient, safe, and effective.

Lastly, the increasing number of government initiatives along with nongovernment organizations have successfully managed to bring a lot of awareness around pollution and smoking that are major causes of COPD, thereby, impacting lifestyle in a positive manner and increase adoption of the drugs for treatment, ultimately, leading to vertical growth.


Request for More Info @


Table of content

1. Key Insights

2. Report Introduction

3. Market Overview at a Glance

4. Executive Summary

5. Key Events

6. Disease Background and Overview

7. Epidemiology and Patient Population

8. Patient Journey

9. Organizations contributing towards Chronic Obstructive Pulmonary Disease (COPD)

10. Marketed Therapies

11. Emerging Drugs

12. Potential of Emerging and Current therapies

13. Chronic Obstructive Pulmonary Disease (COPD): Seven Major Market Analysis

14. KOL Views

15. Market Drivers

16. Market Barriers

17. SWOT Analysis

18. Unmet Needs

19. Reimbursement and Market Access

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

23. About DelveInsight


Consult with our Business Expert @

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: +19193216187
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States

Written By

You may also like:


In a 6-3 ruling, the Supreme Court ruled against the EPA, hindering the government from tackling the climate crisis.


You can’t just ring someone and ask them to fix America. Where would you get the parts, to start with?


A rainbow flag hangs outside the Ibn Rushd-Goethe mosque in Berlin - Copyright AFP GABRIEL BOUYSA mosque in Berlin on Friday became the first...